CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
about
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer.
P2860
CRLX101, a Nanoparticle-Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
CRLX101, a Nanoparticle-Drug C ...... hibiting DNA Repair and HIF1α.
@en
type
label
CRLX101, a Nanoparticle-Drug C ...... hibiting DNA Repair and HIF1α.
@en
prefLabel
CRLX101, a Nanoparticle-Drug C ...... hibiting DNA Repair and HIF1α.
@en
P2093
P2860
P1433
P1476
CRLX101, a Nanoparticle-Drug C ...... hibiting DNA Repair and HIF1α.
@en
P2093
Christian G Peters
Edward G Garmey
Henry P Foote
Joel E Tepper
Kyle C Roche
Lata Jayaraman
Minh Nguyen
Pauline Wu
Scott Eliasof
P2860
P304
P356
10.1158/0008-5472.CAN-15-2951
P407
P577
2016-10-26T00:00:00Z